Related Experiment Videos

Quantitative and qualitative studies of leukaemic cell dipeptidylpeptidases II and IV

C S Scott1, A N Stark, J Minowada

  • 1Department of Haematology, Cookridge Hospital, Leeds, U.K.

Leukemia Research
|January 1, 1988
PubMed

Insights

Dipeptidylpeptidases II and IV levels in leukemia cells showed variations. DAP II was higher in CLL-Pro variants, while DAP IV increased in CD4-positive malignancies, suggesting quantitative differences.

Area of Science:

  • Biochemistry
  • Hematology
  • Immunology

Background:

  • Dipeptidylpeptidases (DAP) II and IV are enzymes with roles in cellular processes.
  • Leukemia involves abnormal proliferation of blood cells, and enzyme expression can be altered.

Purpose of the Study:

  • To determine cellular concentrations of DAP II and IV in leukemia and T-cell lines.
  • To investigate potential diagnostic applications and correlations with specific leukemia subtypes.

Main Methods:

  • Fluorimetric assay was used to quantify DAP II and IV.
  • 152 leukemia cases and 24 T-cell lines were analyzed.
  • Fast Protein Liquid Chromatography (FPLC) gel filtration was used to assess molecular weight.

Main Results:

  • DAP II levels were generally higher in prolymphocytoid chronic lymphocytic leukemia (CLL-Pro) compared to typical CLL.
  • DAP II from leukaemic cells showed consistent molecular weight and substrate affinity.
  • Increased DAP IV levels were associated with CD4-positive postthymic malignancies.
  • DAP IV expression in immature T-cells was independent of differentiation stage or CD4 expression.

Conclusions:

  • Variations in DAP II and IV levels in leukemia appear to be quantitative rather than qualitative.
  • DAP cytochemical staining patterns likely reflect these quantitative differences.
  • No evidence of lineage restriction was found for either enzyme.

Related Concept Videos